Clinical trial

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

NCT00491257 · Sanofi Pasteur, a Sanofi Company, Industry · Completed

Key facts

NCT number NCT00491257
Title A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine
Official title Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)
Lead sponsor Sanofi Pasteur, a Sanofi Company, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Influenza, Orthomyxoviridae Infections
Intervention type Biological
Interventions Inactivated influenza vaccine (split virion) NH 2007-2008 formulation
Enrollment 130
Start date Jun 1, 2007
Primary completion Jul 1, 2007
Completion Jul 1, 2007
First posted Jun 26, 2007
Last update posted Jan 17, 2014
Countries United Kingdom

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies